Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults.
This retrospective chart review evaluated changes in serum creatinine and creatinine clearance (CrCl) after initiation of an integrase inhibitor (INSTI)-based regimen as initial treatment in human immunodeficiency virus-infected adults. Serum creatinine and CrCl changes were similar to those seen in clinical trials for INSTIs. No renal-related serious adverse events or discontinuations occurred.
PGY-2 Infectious Diseases Pharmacy Resident, VA St. Louis Healthcare System , Missouri.
Tara A
TA
Lindeman
Division of Infectious Diseases , College of Medicine and Life Sciences.
Joan M
JM
Duggan
College of Pharmacy and Pharmaceutical Sciences, University of Toledo , Ohio.
Eric G
EG
Sahloff
creatinine clearance; human immunodeficiency virus; integrase inhibitor; renal